Effects of Benazepril on Survival of Dogs with Chronic Kidney Disease: A Multicenter, Randomized, Blinded, Placebo‐Controlled Clinical Trial

Background Chronic kidney disease (CKD) is an important cause of morbidity and mortality in dogs. Objective To evaluate the efficacy in prolonging survival and safety of benazepril administration to dogs with CKD. Animals Forty‐nine client‐owned dogs with CKD. Methods Dogs were randomized to benazep...

Full description

Saved in:

Bibliographic Details
Published in:	Journal of veterinary internal medicine Vol. 31; no. 4; pp. 1113 - 1122
Main Authors:	King, J.N., Font, A., Rousselot, J.‐F., Ash, R.A., Bonfanti, U., Brovida, C., Crowe, I.D., Lanore, D., Pechereau, D., Seewald, W., Strehlau, G.
Format:	Journal Article
Language:	English
Published:	United States John Wiley and Sons Inc 01-07-2017
Subjects:	ACE inhibitor Angiotensin-Converting Enzyme Inhibitors - adverse effects Angiotensin-Converting Enzyme Inhibitors - therapeutic use Animals Benzazepines - adverse effects Benzazepines - therapeutic use Dog Diseases - drug therapy Dogs Female Male Renal Insufficiency, Chronic - drug therapy Renal Insufficiency, Chronic - veterinary Single-Blind Method SMALL ANIMAL Survival Time‐to‐event analysis Treatment failure Treatment Outcome Treatment failure Survival Time-to-event analysis ACE inhibitor
Online Access:	Get full text
Tags:	Add Tag No Tags, Be the first to tag this record!

Description
Summary:	Background Chronic kidney disease (CKD) is an important cause of morbidity and mortality in dogs. Objective To evaluate the efficacy in prolonging survival and safety of benazepril administration to dogs with CKD. Animals Forty‐nine client‐owned dogs with CKD. Methods Dogs were randomized to benazepril (0.25 to <0.5 mg/kg) or placebo once daily for up to 2 years in a prospective, multicenter, blinded clinical trial. The primary endpoint variable was the renal survival time, defined as the time from inclusion in the study to the treatment failure endpoint of death or euthanasia or need for administration of parenteral fluids related to renal failure. Results No benefit of benazepril versus placebo was detected for renal survival time in all dogs; median (95% confidence interval (CI)) survival times were 305 (53–575) days in the benazepril group and 287 (152‐not available) in the placebo group (P = .53). Renal survival times were not significantly longer with benazepril compared to placebo for subgroups: hazard ratios (95% CI) were 0.50 (0.21–1.22) with P = .12 for initial urine protein‐to‐creatinine ratio (UPC) >0.5, and 0.38 (0.12–1.19) with P = .080 for initial UPC >0.5 plus plasma creatinine ≤440 μmol/L. Proteinuria, assessed from the UPC, was significantly (P = .0032) lower after treatment with benazepril compared to placebo. There were no significant differences between groups for clinical signs or frequencies of adverse events. Conclusions and Clinical Relevance Benazepril significantly reduced proteinuria in dogs with CKD. Insufficient numbers of dogs were recruited to allow conclusions on survival time.
ISSN:	0891-6640 1939-1676
DOI:	10.1111/jvim.14726